This was because, prior to this, efgartigimod had not only shown therapeutic value in MG patients with positive AChR antibodies but also exhibited significant response characteristics in a series of special subgroups of MG, such as MG patients with positive MuSK antibodies, isolated ocular myasthenia gravis, and triple-seronegative MG (8–10, 17). This evidence concerns the gene MUSK and myasthenia gravis.